BrainStorm Cell Therapeutics (NASDAQ:BCLI) COO and Chief Medical Officer Ralph Kern sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The biotech is focused on generating top-line results for its ALS Phase 3 and progressive MS Phase 2 trials in Q4 2020 to gain eventual commercialization of its therapy called NurOwn in ALS.
Brainstorm Cell Therapeutics looks forward to top-line results for its ALS Phase 3 program
Quick facts: BrainStorm Cell Therapeutics Inc.
Price: 4.35 USD
Market Cap: $98.34 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE